Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash & Equivalents (2020 - 2023)

Cullinan Therapeutics has reported Cash & Equivalents over the past 4 years, most recently at $64.8 million for Q3 2023.

  • Quarterly results put Cash & Equivalents at $64.8 million for Q3 2023, down 73.28% from a year ago — trailing twelve months through Sep 2023 was $64.8 million (down 73.28% YoY), and the annual figure for FY2022 was $156.2 million, up 161.24%.
  • Cash & Equivalents for Q3 2023 was $64.8 million at Cullinan Therapeutics, down from $491.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CGEM hit a ceiling of $491.8 million in Q2 2023 and a floor of $59.8 million in Q4 2021.
  • Median Cash & Equivalents over the past 4 years was $205.4 million (2020), compared with a mean of $236.4 million.
  • Biggest five-year swings in Cash & Equivalents: surged 185.89% in 2022 and later tumbled 73.28% in 2023.
  • Cullinan Therapeutics' Cash & Equivalents stood at $168.2 million in 2020, then crashed by 64.46% to $59.8 million in 2021, then soared by 161.24% to $156.2 million in 2022, then plummeted by 58.47% to $64.8 million in 2023.
  • The last three reported values for Cash & Equivalents were $64.8 million (Q3 2023), $491.8 million (Q2 2023), and $122.1 million (Q1 2023) per Business Quant data.